AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) saw an upside of 2.57% to $1.14 after adding $0.03 on Tuesday. The 5-day average trading volume is 959,852 shares of the company’s common stock. It has gained $1.3000 in the past week and touched a new high 5 times within the past 5 days. An average of 351,583 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 211,423.
ACRX’s 1-month performance is 12.72% or $0.1000 on its low of $0.7500 reached on 08/15/23. The company’s shares have touched a 52-week low of $0.55 and high of $7.17, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, ACRX has lost -49.62% or -$1.1400 and has reached a new high 3 times. However, the current price is down -84.12% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
ACRX stock has a beta of 0.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 17.95 while the price-to-book (PB) in the most recent quarter is 1.20.
In terms of profitability, the gross margin trailing 12 months is 8.00%. The trailing 12-month EBITDA margin is -1696.10%. The firm’s gross profit as reported stood at -$0.82 million against revenue of $1.77 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 1716.93% to -$4.37 million, while revenue of -$8.15 million was -86.5% off the previous quarter. Analysts expected ACRX to announce -$0.53 per share in earnings in its latest quarter, but it posted -$0.4, representing a 24.50% surprise. EBITDA for the quarter stood at more than -$3.92 million. Shareholders hold equity totaling $16.34 million.
Let’s look briefly at AcelRx Pharmaceuticals Inc. (ACRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 69.94% to suggest the stock is trending Neutral, with historical volatility in this time period at 179.75%.
The stock’s 5-day moving average is $0.9487, reflecting a +46.41% or $0.3550 change from its current price. ACRX is currently trading +9.80% above its 20-day SMA, +55.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -9.68% and SMA200 by-50.66%.
Stochastic %K and %D was 68.52% and 50.61% and the average true range (ATR) pointed at 0.1157. The RSI (14) points at 61.81%, while the 14-day stochastic is at 67.27% with the period’s ATR at 0.1048. The stock’s 9-day MACD Oscillator is pointing at 0.1387 and 0.1102 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Credit Suisse downgraded it to an Underperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ACRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ACRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is ACRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $8.00, with their median price target at $8.00. Looking at these predictions, the average price target given by analysts is for AcelRx Pharmaceuticals Inc. (ACRX) stock is $8.00.
